



DIVE INTO THE DATA AT DDW®

Explore the options for your patients

Join us at our product theater sessions to learn more about our clinical data



ONE TREATMENT WITH TWO OPTIONS: ROUTE OF ADMINISTRATION FLEXIBILITY WITH ENTYVIO (VEDOLIZUMAB)

Michael Chiorean, MD

IBD Lead, Physician Enterprise Puget Sound, Swedish Gastroenterology, Seattle, WA

Sunday, May 19 from 3:20 pm-4:05 pm ET in Product Theater 2

Snacks will be served.



ALL ABOUT THE ENTYVIO (VEDOLIZUMAB) SUBCUTANEOUS PEN

Joshua M. Steinberg, MD

Director of IBD, Gastroenterology of the Rockies, Clinical Instructor of Medicine, University of Colorado School of Medicine, Denver, CO

Monday, May 20 from 10:20 am-11:05 am ET in Product Theater 2

Snacks will be served.

The Product Theater content and views expressed therein are those of the sponsor and not of Digestive Disease Week®

If you are a Colorado prescriber, please see the Colorado WAC disclosure form at [Takeda.info/ENTYVIOCOpricing](https://www.takeda.com/ENTYVIOCOpricing). If you are a Connecticut prescriber, please see the Connecticut WAC disclosure form at [Takeda.info/ENTYVIOCTpricing](https://www.takeda.com/ENTYVIOCTpricing).

©2024 Takeda Pharmaceuticals U.S.A., Inc. 95 Hayden Ave., Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited. ENTYVIO and the ENTYVIO logo are registered trademarks of Millennium Pharmaceuticals, Inc. All other trademarks are the property of their respective owners. US-VED-2750v1.0 05/24

